insights_auto
Outlook: 54.2% bullish·4.2% bearish
Go to analysischevron_right
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
$14.65
0.00%
(0.00) 1D
$14.58
arrow_downward
-0.48% (-0.071)todayPre-market
Closed: Sep 21, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RARE...
Mkt. cap
1.44B
Avg. vol.
4.78M
Volume
21.06K
52-wk high
$39.89
52-wk low
$12.73
EPS
-$5.84
Beta
0.32
Shares outstanding
98.59M
No. of employees
1K
Mkt. cap
1.44B
Avg. vol.
4.78M
Volume
21.06K
52-wk high
$39.89
52-wk low
$12.73
EPS
-$5.84
Beta
0.32
Shares outstanding
98.59M
No. of employees
1K
News stories
From web sources and news partners
Yahoo Finance
·
3 hours ago
FDA Approves Fayuvi. What Does It Mean for Ultragenyx (RARE)’s 2027 Profitability Target?
The Globe and Mail
·
12 hours ago
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE)
Investing.com
·
21 hours ago
Is Ultragenyx Stock a Buy With 2 FDA Vouchers Worth a Quarter of Its Market Value?
AD HOC NEWS
·
2 days ago
Ultragenyx Pharmaceutical stock gains after FDA approval and fresh analyst targets
Profile
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
About Ultragenyx Pharmaceutical Inc
CEOEmil Kakkis
Employees1.37K
Founded2010
HeadquartersNovato, California, United States
SectorBiotechnology
Websiteultragenyx.com